Abstract

Inflammatory bowel disease (IBD) is a disease that causes inflammation throughout the digestive tract. Repeated inflammation and frequent relapses cause intestinal damage and expose the patient to a higher risk. In this work, we proposed an immune therapy model for effective treatment strategy through mathematical modeling for patients with IBD. We evaluated the ability of the patient’s immune system to recover during treatment. For this, we defined the interval of healthy individual, and examined the frequency of compartments such as T cells and cytokines considered in the model maintain the normal state. Based on the fact that each patient has a unique immune system, we have shown at the same drug works differently, depending on the individual immune system characteristics for every patient. It is known that IBD is related to an imbalance between pro- and anti- inflammatory cytokines as the cause of the disease. So the ratios of pro- to anti- inflammatory cytokines are used as an indicator of patient’s condition and inflammation status in various diseases. We compared the ratios of pro- to anti- inflammatory cytokine according to patient’s individual immune system and drugs. Since the effects of biological drugs are highly dependent on the patient’s own immune system, it is essential to define the immune system status before selecting and using a biological drug.

Highlights

  • Inflammatory bowel disease (IBD) causes inflammation in the digestive system and is characterized by a disproportion of cytokines in the affected patients [1, 2]

  • Inflammatory processes lead to increased pro-inflammatory cytokine levels, mediated by a T cell response

  • Combining treatment with a mathematical model based on the abnormal immune response of IBD, we develop an immune therapy model for suggesting the order of treatment for IBD

Read more

Summary

An immune therapy model for effective treatment on inflammatory bowel disease

OPEN ACCESS Citation: Park A, Kim S, Jung IH, Byun JH (2020) An immune therapy model for effective treatment on inflammatory bowel disease. Editor: Pinyi Lu, Biotechnology HPC Software Applications Institute (BHSAI), UNITED STATES

Introduction
Materials and methods
Injection of the drugs δDα
Ig þ
Findings
Author Contributions

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.